A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot

Yuan Hwa Chou, Po Chung Chu, Szu Wei Wu, Jen Chin Lee, Yi Hsuan Lee, I. Wen Sun, Chen Lin Chang, Chien Liang Huang, I. Chao Liu, Chia Fen Tsai, Yung Chieh Yen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Bipolar disorder (BD) is a major psychiatric disorder that is easily misdiagnosed. Patient adherence to a treatment regimen is of utmost importance for successful outcomes in BD. Several trials of antipsychotics suggested that depot antipsychotics, including long-acting first- and second-generation agents, are effective in preventing non-adherence, partial adherence, and in reducing relapse in BD. Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole monohydrate. Due to the increasing number of BD patients receiving LAI antipsychotics, treatment guidelines have been developed. However, the clinical applicability of LAI antipsychotics remains a global cause for concern, particularly in Asian countries. Expert physicians from Taiwan participated in a consensus meeting, which was held to review key areas based on both current literature and clinical practice. The purpose of this meeting was to generate a practical and implementable set of recommendations for LAI antipsychotic use to treat BD; target patient groups, dosage, administration, and adverse effects were considered. Experts recommended using LAI antipsychotics in patients with schizophrenia, rapid cycling BD, BD I, and bipolar-type schizoaffective disorder. LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician's clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalClinical Psychopharmacology and Neuroscience
Volume13
Issue number2
DOIs
Publication statusPublished - Aug 1 2015
Externally publishedYes

Fingerprint

Bipolar Disorder
Consensus
Antipsychotic Agents
Injections
olanzapine
Physicians
Risperidone
Patient Compliance
Diagnostic Errors
Taiwan
Microspheres
Psychotic Disorders
Psychiatry
Schizophrenia
Guidelines
Recurrence
Therapeutics

Keywords

  • Bipolar disorder
  • Consensus
  • Long-acting injectable antipsychotics
  • Risperidone

ASJC Scopus subject areas

  • Behavioral Neuroscience
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Chou, Y. H., Chu, P. C., Wu, S. W., Lee, J. C., Lee, Y. H., Sun, I. W., ... Yen, Y. C. (2015). A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot. Clinical Psychopharmacology and Neuroscience, 13(2), 121-128. https://doi.org/10.9758/cpn.2015.13.2.121

A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot. / Chou, Yuan Hwa; Chu, Po Chung; Wu, Szu Wei; Lee, Jen Chin; Lee, Yi Hsuan; Sun, I. Wen; Chang, Chen Lin; Huang, Chien Liang; Liu, I. Chao; Tsai, Chia Fen; Yen, Yung Chieh.

In: Clinical Psychopharmacology and Neuroscience, Vol. 13, No. 2, 01.08.2015, p. 121-128.

Research output: Contribution to journalArticle

Chou, YH, Chu, PC, Wu, SW, Lee, JC, Lee, YH, Sun, IW, Chang, CL, Huang, CL, Liu, IC, Tsai, CF & Yen, YC 2015, 'A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot', Clinical Psychopharmacology and Neuroscience, vol. 13, no. 2, pp. 121-128. https://doi.org/10.9758/cpn.2015.13.2.121
Chou, Yuan Hwa ; Chu, Po Chung ; Wu, Szu Wei ; Lee, Jen Chin ; Lee, Yi Hsuan ; Sun, I. Wen ; Chang, Chen Lin ; Huang, Chien Liang ; Liu, I. Chao ; Tsai, Chia Fen ; Yen, Yung Chieh. / A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot. In: Clinical Psychopharmacology and Neuroscience. 2015 ; Vol. 13, No. 2. pp. 121-128.
@article{ae6fa64dbbdd481d8bc09b2a16c4378a,
title = "A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot",
abstract = "Bipolar disorder (BD) is a major psychiatric disorder that is easily misdiagnosed. Patient adherence to a treatment regimen is of utmost importance for successful outcomes in BD. Several trials of antipsychotics suggested that depot antipsychotics, including long-acting first- and second-generation agents, are effective in preventing non-adherence, partial adherence, and in reducing relapse in BD. Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole monohydrate. Due to the increasing number of BD patients receiving LAI antipsychotics, treatment guidelines have been developed. However, the clinical applicability of LAI antipsychotics remains a global cause for concern, particularly in Asian countries. Expert physicians from Taiwan participated in a consensus meeting, which was held to review key areas based on both current literature and clinical practice. The purpose of this meeting was to generate a practical and implementable set of recommendations for LAI antipsychotic use to treat BD; target patient groups, dosage, administration, and adverse effects were considered. Experts recommended using LAI antipsychotics in patients with schizophrenia, rapid cycling BD, BD I, and bipolar-type schizoaffective disorder. LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician's clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.",
keywords = "Bipolar disorder, Consensus, Long-acting injectable antipsychotics, Risperidone",
author = "Chou, {Yuan Hwa} and Chu, {Po Chung} and Wu, {Szu Wei} and Lee, {Jen Chin} and Lee, {Yi Hsuan} and Sun, {I. Wen} and Chang, {Chen Lin} and Huang, {Chien Liang} and Liu, {I. Chao} and Tsai, {Chia Fen} and Yen, {Yung Chieh}",
year = "2015",
month = "8",
day = "1",
doi = "10.9758/cpn.2015.13.2.121",
language = "English",
volume = "13",
pages = "121--128",
journal = "Clinical Psychopharmacology and Neuroscience",
issn = "1738-1088",
publisher = "Korean College of Neuropsychopharmacology",
number = "2",

}

TY - JOUR

T1 - A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychot

AU - Chou, Yuan Hwa

AU - Chu, Po Chung

AU - Wu, Szu Wei

AU - Lee, Jen Chin

AU - Lee, Yi Hsuan

AU - Sun, I. Wen

AU - Chang, Chen Lin

AU - Huang, Chien Liang

AU - Liu, I. Chao

AU - Tsai, Chia Fen

AU - Yen, Yung Chieh

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Bipolar disorder (BD) is a major psychiatric disorder that is easily misdiagnosed. Patient adherence to a treatment regimen is of utmost importance for successful outcomes in BD. Several trials of antipsychotics suggested that depot antipsychotics, including long-acting first- and second-generation agents, are effective in preventing non-adherence, partial adherence, and in reducing relapse in BD. Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole monohydrate. Due to the increasing number of BD patients receiving LAI antipsychotics, treatment guidelines have been developed. However, the clinical applicability of LAI antipsychotics remains a global cause for concern, particularly in Asian countries. Expert physicians from Taiwan participated in a consensus meeting, which was held to review key areas based on both current literature and clinical practice. The purpose of this meeting was to generate a practical and implementable set of recommendations for LAI antipsychotic use to treat BD; target patient groups, dosage, administration, and adverse effects were considered. Experts recommended using LAI antipsychotics in patients with schizophrenia, rapid cycling BD, BD I, and bipolar-type schizoaffective disorder. LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician's clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.

AB - Bipolar disorder (BD) is a major psychiatric disorder that is easily misdiagnosed. Patient adherence to a treatment regimen is of utmost importance for successful outcomes in BD. Several trials of antipsychotics suggested that depot antipsychotics, including long-acting first- and second-generation agents, are effective in preventing non-adherence, partial adherence, and in reducing relapse in BD. Various long-acting injectable (LAI) antipsychotics are available, including fluphenazine decanoate, haloperidol decanoate, olanzapine pamoate, risperidone microspheres, paliperidone palmitate, and aripiprazole monohydrate. Due to the increasing number of BD patients receiving LAI antipsychotics, treatment guidelines have been developed. However, the clinical applicability of LAI antipsychotics remains a global cause for concern, particularly in Asian countries. Expert physicians from Taiwan participated in a consensus meeting, which was held to review key areas based on both current literature and clinical practice. The purpose of this meeting was to generate a practical and implementable set of recommendations for LAI antipsychotic use to treat BD; target patient groups, dosage, administration, and adverse effects were considered. Experts recommended using LAI antipsychotics in patients with schizophrenia, rapid cycling BD, BD I, and bipolar-type schizoaffective disorder. LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician's clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.

KW - Bipolar disorder

KW - Consensus

KW - Long-acting injectable antipsychotics

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=84939560557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939560557&partnerID=8YFLogxK

U2 - 10.9758/cpn.2015.13.2.121

DO - 10.9758/cpn.2015.13.2.121

M3 - Article

AN - SCOPUS:84939560557

VL - 13

SP - 121

EP - 128

JO - Clinical Psychopharmacology and Neuroscience

JF - Clinical Psychopharmacology and Neuroscience

SN - 1738-1088

IS - 2

ER -